Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01901146
Title Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac)
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements No
Sponsors Amgen

Her2-receptor positive breast cancer


Cyclophosphamide + Epirubicin

Paclitaxel + Trastuzumab

Age Groups: adult
Covered Countries CAN

No variant requirements are available.